Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
about
Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous MelanomaPhenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.
P2860
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Adjuvant Autologous Melanoma V ...... d Response to CTLA-4 Blockade.
@en
type
label
Adjuvant Autologous Melanoma V ...... d Response to CTLA-4 Blockade.
@en
prefLabel
Adjuvant Autologous Melanoma V ...... d Response to CTLA-4 Blockade.
@en
P2093
P2860
P356
P1476
Adjuvant Autologous Melanoma V ...... ed Response to CTLA-4 Blockade
@en
P2093
Ali Osmay Gure
Aviram Nissan
Bilal Alaiyan
Einat Carmon
Eitan Shiloni
Galit Eisenberg
Hanna Steinberg
Kerem Mert Senses
Luna Kadouri
P2860
P304
P356
10.1155/2016/8121985
P577
2016-05-18T00:00:00Z